TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06402201: First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors

Sponsor: CDR-Life AG · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 42 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$2,230,536

Rescue Site Savings

+$1,476,552

Unlock Full NCT06402201 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06402201 Rescue Dossier →